Literature DB >> 28879633

The Initial Evaluation and Management of a Patient with Heart Failure.

Jamael Hoosain1, Jabar Whittier1, Farhan Hasni1, Shelley Hankins2.   

Abstract

PURPOSE OF REVIEW: The goal of this review is to summarize and discuss a thorough and effective manner in the evaluation of the patient with heart failure. RECENT
FINDINGS: Heart failure is a prevalent disease worldwide and while the diagnosis of heart failure has remained relatively unchanged via a careful history and physical examination, identification of the etiology of the heart failure and treatment has made significant advances. Mechanical circulatory support (MCS), neprilysin inhibitors, and chronic resynchronization therapy (CRT) are just some of the relatively recent therapies afforded to assist heart failure patients. Heart failure is a complicated, multifactorial diagnosis that requires a careful history and physical for diagnosis with the support of laboratory tests. While the prognosis for heart failure patients remains poor in comparison to other cardiovascular disease and even certain cancers, new advancements in therapy have shown survival and quality of life improvement.

Entities:  

Keywords:  Cardiomyopathy; Heart failure; Hypertension

Mesh:

Substances:

Year:  2017        PMID: 28879633     DOI: 10.1007/s11886-017-0900-8

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  92 in total

1.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

Authors:  Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

2.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

3.  Progression of left ventricular diastolic dysfunction and risk of heart failure.

Authors:  Garvan C Kane; Barry L Karon; Douglas W Mahoney; Margaret M Redfield; Veronique L Roger; John C Burnett; Steven J Jacobsen; Richard J Rodeheffer
Journal:  JAMA       Date:  2011-08-24       Impact factor: 56.272

4.  Diuretic strategies in patients with acute decompensated heart failure.

Authors:  G Michael Felker; Kerry L Lee; David A Bull; Margaret M Redfield; Lynne W Stevenson; Steven R Goldsmith; Martin M LeWinter; Anita Deswal; Jean L Rouleau; Elizabeth O Ofili; Kevin J Anstrom; Adrian F Hernandez; Steven E McNulty; Eric J Velazquez; Abdallah G Kfoury; Horng H Chen; Michael M Givertz; Marc J Semigran; Bradley A Bart; Alice M Mascette; Eugene Braunwald; Christopher M O'Connor
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

5.  Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study).

Authors:  Jennifer E Ho; David D Waters; Allison Kean; Daniel J Wilson; David A Demicco; Andrei Breazna; Chuan-Chuan Wun; Prakash C Deedwania; Kiran K Khush
Journal:  Am J Cardiol       Date:  2012-03-28       Impact factor: 2.778

6.  Discharge education improves clinical outcomes in patients with chronic heart failure.

Authors:  Todd M Koelling; Monica L Johnson; Robert J Cody; Keith D Aaronson
Journal:  Circulation       Date:  2005-01-10       Impact factor: 29.690

Review 7.  Advanced heart failure: a call to action.

Authors:  Stuart D Russell; Leslie W Miller; Francis D Pagani
Journal:  Congest Heart Fail       Date:  2008 Nov-Dec

8.  Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.

Authors:  Paolo Verdecchia; Peter Sleight; Giuseppe Mancia; Robert Fagard; Bruno Trimarco; Roland E Schmieder; Jae-Hyung Kim; Garry Jennings; Petr Jansky; Jyh-Hong Chen; Lisheng Liu; Peggy Gao; Jeffrey Probstfield; Koon Teo; Salim Yusuf
Journal:  Circulation       Date:  2009-09-21       Impact factor: 29.690

9.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

10.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.